Is the active ingredient. it's a form of erythropoiesis-stimulating agent (esa).
Treatment of anemia associated with chronic kidney disease (CKD)
Treatment of anemia in patients with nonmyeloid malignancies receiving chemotherapy
Treatment of anemia in patients undergoing surgery with a high risk of blood loss
Nexesa 100mcg Injection (Darbepoetin Alfa) stimulates erythropoiesis (red blood cell production) in the bone marrow by binding to erythropoietin receptors on erythroid progenitor cells. This leads to an increase in red blood cell mass, hemoglobin levels, and hematocrit.
Store in the refrigerator (2-8°C). Do not freeze. Protect from light. Discard any unused portion after the expiration date.
Dosage is determined by the physician based on individual patient needs and response. It is usually administered subcutaneously (under the skin).
The initial dose and subsequent dose adjustments should be guided by hemoglobin levels and other clinical factors.
Follow your doctor's instructions carefully regarding dosage and frequency of injection.
Redness, pain, or swelling at the injection site
Hypertension (high blood pressure)
Headache
Nausea
Vomiting
Thromboembolic events (blood clots)
The effect of alcohol consumption on darbepoetin alfa is not well-established; consult your physician.
Drowsiness or dizziness may occur; avoid operating machinery if affected.
Use only when clearly needed and under strict medical supervision. The potential risks to the fetus or infant should be carefully weighed against the benefits.
Use in children is limited. Dosage and safety should be carefully monitored by a pediatrician.
Caution is needed in patients with impaired kidney function, as the drug is primarily excreted by the kidneys.
Limited data is available on the effect of liver impairment. Physician consultation is essential.
Consult your physician or pharmacist for detailed information and references.
Refer to the official prescribing information provided by the manufacturer.
